G7 health ministers have endorsed a roadmap to speed up delivery of the cancer commitments G7 leaders made in June. France’s G7 presidency published the text on October 19, 2026. It concentrates on two areas: cross-border access to data on cancers in children, adolescents and young adults, and cancers with poor prognosis, such as pancreatic and lung cancer.
For pharmaceutical, diagnostics, medical technology and health data companies, the roadmap shows where G7 governments intend to coordinate: registry interoperability, clinical trial cooperation, screening programs and the use of artificial intelligence in cancer care.
The case the ministers make
The roadmap says cancer causes nearly 10 million deaths a year worldwide and that new cases are expected to rise by 80% globally by 2050, driven by population aging and environmental and behavioral risk factors. It says lung cancer alone accounts for 12% of all cancers and 18% of cancer deaths worldwide, and that its incidence among women is rising by about 5% a year.
It builds on the G7 leaders’ call on the fight against cancer, published June 17, 2026. In that text, leaders committed to work on pediatric cancers, cancers with poor prognosis and access to care, and to significantly reduce lung cancer mortality within ten years.
Two pillars
The first pillar covers cancers in children, adolescents and young adults. Because many of these cancers are rare and highly varied, the roadmap says no single country can produce robust enough data on its own. Ministers say they intend to promote cooperation among existing data programs to network national registries, advance interoperability standards and support the integration of clinical, genomic and imaging data without requiring direct data transfers. The roadmap says this should follow applicable legal and regulatory frameworks and may draw on AI where appropriate.
The second pillar covers cancers with poor prognosis. The roadmap says that for these cancers, fewer than 25% of patients remain disease-free in the first year after treatment and five-year survival is below 30%. Ministers intend to support work toward a shared international definition and research agenda, set ambitious targets for screening and for the share of cancers diagnosed at stage I, as appropriate to national systems, and improve cooperation on clinical trials. The text also encourages evidence-based lung cancer screening programs for eligible populations and names Cancer Grand Challenges among the existing initiatives to build on, subject to available resources.
What it means for business
The roadmap is voluntary. Its commitments are conditioned throughout on national law, priorities, capacities and resources, and it does not announce new funding. It does signal the areas where public health systems in G7 countries plan to align: privacy-preserving data analysis, molecular characterization and biomarkers, earlier diagnosis, innovative clinical trial designs and access to new therapies.
The text also states that access to safe and effective antimicrobials, including antibiotics, remains essential to prevent and treat infections linked to many cancer treatments. It says an informal coordination group of national cancer institutes and research organizations intends to help align existing initiatives to support implementation.















